Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXNXNYSE:GKOSNASDAQ:IRTCNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXNXAxonics$70.98$70.61$66.59▼$71.05$3.63B0.82400,300 shsN/AGKOSGlaukos$94.57+5.1%$94.52$77.10▼$163.71$5.40B0.83679,620 shs735,281 shsIRTCiRhythm Technologies$137.80+0.1%$107.51$55.92▼$141.39$4.40B1.34467,781 shs579,343 shsTNDMTandem Diabetes Care$23.45+2.0%$18.75$15.75▼$53.69$1.56B1.471.50 million shs2.40 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXNXAxonics0.00%0.00%0.00%0.00%+5.26%GKOSGlaukos+5.15%+8.95%+5.02%-34.79%-14.39%IRTCiRhythm Technologies+0.07%+1.50%+34.98%+28.92%+39.18%TNDMTandem Diabetes Care+2.05%+10.15%+37.46%-30.04%-47.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXNXAxonicsN/AN/AN/AN/AN/AN/AN/AN/AGKOSGlaukos4.8505 of 5 stars4.44.00.04.44.12.50.6IRTCiRhythm Technologies1.0261 of 5 stars2.51.00.00.03.50.00.6TNDMTandem Diabetes Care4.7661 of 5 stars4.34.00.04.93.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXNXAxonics 2.00HoldN/AN/AGKOSGlaukos 2.75Moderate Buy$134.6742.40% UpsideIRTCiRhythm Technologies 2.91Moderate Buy$128.55-6.72% DownsideTNDMTandem Diabetes Care 2.53Moderate Buy$39.8169.78% UpsideCurrent Analyst Ratings BreakdownLatest AXNX, TNDM, GKOS, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.005/2/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$104.00 ➝ $130.005/2/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $151.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.005/1/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXNXAxonics$366.38M9.90$0.13 per share561.96$12.59 per share5.64GKOSGlaukos$404.52M13.36N/AN/A$9.46 per share10.00IRTCiRhythm Technologies$618.59M7.11N/AN/A$6.85 per share20.12TNDMTandem Diabetes Care$982.95M1.59N/AN/A$4.81 per share4.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXNXAxonics-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/AGKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)IRTCiRhythm Technologies-$123.41M-$3.14N/AN/AN/A-19.14%-118.83%-11.34%N/ATNDMTandem Diabetes Care-$222.61M-$2.78N/AN/AN/A-14.84%-44.19%-11.99%N/ALatest AXNX, TNDM, GKOS, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million2/20/2025Q4 2024GKOSGlaukos-$0.38-$0.40-$0.02-$0.60$100.72 million$105.50 million2/20/2025Q4 2024IRTCiRhythm Technologies-$0.29$0.01+$0.30-$0.04$158.30 million$164.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXNXAxonicsN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXNXAxonicsN/A8.166.40GKOSGlaukos0.195.544.71IRTCiRhythm Technologies9.006.276.12TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXNXAxonics99.48%GKOSGlaukos99.04%IRTCiRhythm TechnologiesN/ATNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipAXNXAxonics1.85%GKOSGlaukos5.80%IRTCiRhythm Technologies1.10%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXNXAxonics61051.11 million50.16 millionOptionableGKOSGlaukos78057.14 million51.61 millionOptionableIRTCiRhythm Technologies1,79031.93 million31.09 millionOptionableTNDMTandem Diabetes Care2,60066.61 million64.23 millionOptionableAXNX, TNDM, GKOS, and IRTC HeadlinesRecent News About These CompaniesNorthern Trust Corp Purchases 61,768 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 13 at 3:48 AM | marketbeat.comTandem Diabetes Care: Promising Growth Driven by Robust Pipeline and Strategic InitiativesMay 12 at 10:15 AM | tipranks.comFrontier Capital Management Co. LLC Has $9.80 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 12 at 5:35 AM | marketbeat.comFred Alger Management LLC Sells 35,763 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 10 at 8:16 AM | marketbeat.comDAFNA Capital Management LLC Buys 19,000 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 10 at 7:30 AM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Algert Global LLCMay 10 at 4:56 AM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Divisadero Street Capital Management LPMay 9, 2025 | marketbeat.comBrevan Howard Capital Management LP Boosts Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 9, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $39.81 Consensus Target Price from BrokeragesMay 9, 2025 | americanbankingnews.com913,087 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Bought by Brown Advisory Inc.May 8, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8, 2025 | marketbeat.comFirst Trust Advisors LP Decreases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 7, 2025 | marketbeat.comTandem Diabetes Care Announces Upcoming Conference PresentationsMay 6, 2025 | gurufocus.comTandem Diabetes Care Announces Upcoming Conference PresentationsMay 6, 2025 | businesswire.comBellevue Group AG Cuts Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 6, 2025 | marketbeat.comBeaconlight Capital LLC Has $11.93 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 6, 2025 | marketbeat.comHsbc Holdings PLC Purchases 14,501 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 6, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic Outlook of TNDM Q2 EarningsMay 6, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Purchases 337,026 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 5, 2025 | marketbeat.comFreestone Grove Partners LP Invests $6.52 Million in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 5, 2025 | marketbeat.comLeerink Partnrs Issues Negative Forecast for TNDM EarningsMay 5, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXNX, TNDM, GKOS, and IRTC Company DescriptionsAxonics NASDAQ:AXNXAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Glaukos NYSE:GKOS$94.57 +4.61 (+5.12%) Closing price 05/12/2025 03:59 PM EasternExtended Trading$94.08 -0.49 (-0.52%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.iRhythm Technologies NASDAQ:IRTC$137.80 +0.10 (+0.07%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$137.72 -0.09 (-0.06%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Tandem Diabetes Care NASDAQ:TNDM$23.45 +0.47 (+2.05%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$23.54 +0.10 (+0.41%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
